Unlike the high efficacy of BRAF targeting strategies observed in melanoma, monotherapy with V600E-specific kinase inhibitors (vemurafenib, dabrafenib) has been proven to be ineffective in metastatic colorectal cancer (mCRC) [11]. Here, BRAF is linked to melanoma.